145547-97-3

Basic information

• Product Name: Benzenemethanol, 4-bromo-3-nitro-
• CAS NO: 145547-97-3
• Molecular Formula: C7H6BrNO3
• Molecular Weight: 232.034
• Mol File: 145547-97-3.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Benzenemethanol, 4-bromo-3-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanol, 4-bromo-3-nitro-(145547-97-3)
• EPA Substance Registry System: Benzenemethanol, 4-bromo-3-nitro-(145547-97-3)

Safety Data

• Hazardous Substances Data: 145547-97-3(Hazardous Substances Data)

Usage

Description

Benzenemethanol, 4-bromo-3-nitro-, also known as 4-Bromo-3-nitrobenzenemethanol, is a chemical compound with the molecular formula C7H6BrNO3. It is a white to off-white crystalline powder that is used in the production of pharmaceuticals and other organic compounds. This chemical is known for its anti-inflammatory and analgesic properties, and is commonly used in the synthesis of drugs for pain relief and muscle relaxation. It is important to handle this compound with care and to use proper protective equipment when working with it, as it can be harmful if ingested or absorbed through the skin.

Uses

Used in Pharmaceutical Industry:
Benzenemethanol, 4-bromo-3-nitrois used as an intermediate in the synthesis of drugs for pain relief and muscle relaxation. Its anti-inflammatory and analgesic properties make it a valuable component in the development of medications to treat various conditions such as headaches, muscle aches, and inflammation.
Used in Organic Synthesis:
Benzenemethanol, 4-bromo-3-nitrois also used as a building block in the synthesis of other organic compounds. Its unique structure allows it to be a versatile starting material for the production of various chemical products, including dyes, agrochemicals, and other specialty chemicals.

Upstream product

• 163596-75-6 4-bromo-3-nitrobenzaldehyde 
• 6319-40-0 4-bromo-3-nitrobenzoic acid 

Downstream Products

• 1330633-54-9 4-bromo-3-nitrobenzylsulfonylacetic acid 
• 1330633-74-3 (E)-2',4',6'-trimethoxystyryl-4-bromo-3-nitrobenzylsulfone 
• 851799-35-4 (E)-2',4',6'-trimethoxystyryl-4-bromo-3-aminobenzylsulfone 
• 1330633-50-5 4-bromo-3-nitrobenzylthioacetic acid 
• 326595-66-8 2-bromo-5-(bromomethyl)-1-nitrobenzene 

Relevant articles and documents

New tetrahydroisoquinoline-based P-glycoprotein modulators: Decoration of the biphenyl core gives selective ligands

P-glycoprotein (P-gp, MDR1) is a membrane transporter expressed in several regions of our body. It plays a crucial defense role as it mediates the efflux of hundreds of potentially toxic substances. However, P-gp is one of the main causes of failure in ca

Metal–Organic Framework-Encapsulated CoCu Nanoparticles for the Selective Transfer Hydrogenation of Nitrobenzaldehydes: Engineering Active Armor by the Half-Way Injection Method

A novel armor-type composite of metal–organic framework (MOF)-encapsulated CoCu nanoparticles with a Fe3O4 core (Fe3O4@SiO2-NH2-CoCu@UiO-66) has been designed and synthesized by the half-way injection method, which successfully serves as an efficient and recyclable catalyst for the selective transfer hydrogenation. In this half-way injection approach, the pre-synthetic Fe3O4@SiO2-NH2-CoCu was injected into the UiO-66 precursor solution halfway through the MOF budding period. The formed MOF armor could play a role of providing significant additional catalytic sites besides CoCu nanoparticles, protecting CoCu nanoparticles, and improving the catalyst stability, thus facilitating the selective transfer hydrogenation of nitrobenzaldehydes into corresponding nitrobenzyl alcohols in high selectivity (99 %) and conversion (99 %) rather than nitro group reduction products. Notably, this method achieves the precise assembly of a MOF-encapsulated composite, and the ingenious combination of MOF and nanoparticles exhibits excellent catalytic performance in the selective hydrogen transfer reaction, implementing a “1+1>2” strategy in catalysis.

Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2′,4′,6′-trimethoxystyrylsulfonyl)methyl] phenylamino}acetate (ON 01910.Na): Synthesis, structure-activity relationship, and biological activity

Cyclin D proteins are elevated in many cancer cells, and targeted deletion of cyclin D1 gene in the mammary tissues protects mice from breast cancer. Accordingly, there is an increasing awareness of this novel nonenzymatic target for cancer therapeutics. We have developed novel, nonalkylating styrylbenzylsulfones that induce cell death in wide variety of cancer cells without affecting the proliferation and survival of normal cells. The development of derivatized styrylbenzylsulfones followed logically from a tumor cell cytotoxicity screen performed in our laboratory that did not have an a priori target profile. Modifications of some of the precursor molecules led to lead optimization with regard to tumor cell cytotoxicity. In this report we describe the synthesis and structure-activity relationships of novel, nonalkylating (E)-styrylbenzylsulfones and the development of the novel anticancer agent sodium (E)-2-{2-methoxy-5-[(2′,4′,6′- trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na), which is in phase III trials for myelodysplastic syndromes (MDS) associated with aberrant expression of cyclin D proteins.